Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 5 Issue 11

In silico Evaluation of Solanine Compound as New Potential Inhibitors of Cancer Causing Enzymes

Rajalakshmi A1* and Jayachitra A2

1Assistant Professor, Department of Biotechnology, Sri Kaliswari College (Autonomous), Sivakasi, India
2Assistant Professor, Department of Plant Biotechnology, School of Biotechnology, Madurai Kamaraj University, Madurai, India

*Corresponding Author: Rajalakshmi A, Assistant Professor, Department of Biotechnology, Sri Kaliswari College (Autonomous), Sivakasi, India.

Received: August 24, 2021; Published: October 11, 2021

×

Abstract

Explore the interaction mode and binding orientation of lead compound with target proteins by molecular docking studies and understand the structural insights and functional properties of potent target protein by autodock tools. Aim of this study to analyze the interaction of Solanine with cancer causing enzymes. Cyclin-dependent kinase 6, Cytochrome P450, Topoisomerase I, Topo IIa ATPase, anti-apoptotic protein Bcl-2 and Vegfr2 are critical molecules that control cell cycle progression from one phase to the other. However, mutational changes in these molecules lead to the purturbed cell cycle leading to uncontrolled cellular proliferation or cell death. Docking pose is almost close to the substrates for most of the receptors. Remarkably 1t8i - Topoisomerase I and 1zxm - TopoIIa ATPase docking was completely blocking the binding of the substrate with high affinity by the action of Solanine. The molecular docking was applied to explore the binding mechanism and to correlate its docking score with the activity of plant derived compounds.

Keywords: Solanine; Auotdock; Topoisomerase; Molecular Docking; Cell Cycle

×

References

  1. Nilsson and Fredrik. Glycoalkaloid content in potato tubers with different levels of resistance to phytophthora infestans, Thirteenth Euroblight workshop St. Petersbug (Russia) (2011): 9-12 .
  2. Heena V Sanghani., et al. “Molecular Docking Studies of Potent Anticancer Agen”. Journal of Computer Science and Systems Biology 1 (2012): 012-015.
  3. Indian Journal of Medical and Paediatric Oncology 30.1 (2009): 1-8.
  4. , et al. Journal of Advanced Scientific Research 1 (2010): 67-72.
  5. Liao JJ. Journal of Medicinal Chemistry3 (2007): 409-424.
  6. Srivastave V., et al. “Molecular docking studies on DMDP derivatives as human DHFR inhibitors”. Bioinformation 3 (2008): 180-188.
  7. Lemmon M and Schlessinger J. Cell7 (2010): 1117-1134.
  8. Visentin M., et al. Pharmacology Therapy1 (2010): 82-90.
  9. Pallis AG and Syrigos KS. Lung Cancer2 (2013): 120-130.
  10. Polverini PJ. Critical Reviews in Oral Biology and Medicine 3 (1996): 230-247.
  11. Balaji KS., et al. Medicinal Chemistry 6 (2016): 515-520.
  12. Yan Qiu Meng., et al. “Synthesis of Boswellic acid derivatives and primary research on their activities”. Chinese Chemical Letters 16 (2005): 867-870.
×

Citation

Citation: Rajalakshmi A and Jayachitra A. “In silico Evaluation of Solanine Compound as New Potential Inhibitors of Cancer Causing Enzymes". Acta Scientific Pharmaceutical Sciences 5.11 (2020): 20-23.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor1.020

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is January 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US